Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo

Journal of Neurochemistry

Volumn 67, Issue 4, 1996, Pages 1532-1539

  Lamensdorf, Itschak ^a   Youdim, Moussa B H ^a   Finberg, John P M ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Clorgyline; Deprenyl; Dopamine; Microdialysis; Monoamine oxidase; TVP 1012

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; CLORGYLINE; DOPAMINE; MONOAMINE OXIDASE INHIBITOR; SELEGILINE;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE METABOLISM; DOPAMINE RELEASE; DRUG MECHANISM; ENZYME INHIBITION; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALIA; GYMNOMYZA SAMOENSIS;

EID: 0029832455     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1996.67041532.x     Document Type: Article

References (56)

1. Arbuthnott G. W., Fairbrother I. S., and Butcher S. P. (1990) Dopamine release and metabolism in the rat striatum: an analysis by "in vivo" brain microdialysis. Pharmacol. Ther. 48, 281-293.
2. Azzaro A. J., King J., Kotzuk J., Schoepp D. D., Forst J., and Schochet S. (1985) Guinea pig striatum as a model of human dopamine deamination: the role of monoamine oxidase isozyme ratio, localization, and affinity for substrate in synaptic dopamine metabolism. J. Neurochem. 45, 949-956.
3. Butcher S. P., Fairbrother I. S., Kelly J. S., and Arbuthnott G. W. (1990) Effects of selective monoamine oxidase inhibitors on the in vivo release and metabolism of dopamine in the rat striatum. J. Neurochem. 55, 981-988.
4. Chiueh C. C. and Moore K. E. (1974) Relative potencies of d- and l-amphetamine on the release of dopamine from cat brain in vivo. Res. Commun. Chem. Pathol. Pharmacol. 7, 189-199.
5. Colzi A., d'Agostini F., Kettler R., Borroni E., and Da Prada M. (1990) Effect of selective and reversible MAO inhibitors on dopamine outflow in rat striatum; a microdialysis study. J. Neural Transm. Suppl. 32, 79-84.
6. Dluzen D. E. and McDermott J. L. (1991) The effect of long-term treatment with deprenyl on basal and L-DOPA evoked dopamine release in vitro from the corpus striatum of aged rats. J. Neural Transm. Gen. Sect. 85, 145-156.
7. Ekstedt B., Magyar K., and Knoll J. (1979) Does the B form selective monoamine oxidase inhibitor lose selectivity by long term treatment? Biochem. Pharmacol. 28, 919-923.
8. Elsworth J. D., Glover V., Reynolds G. P., Sandier M., Lees A. J., Phuapradit P., Shaw K. M., Stern G. M., and Kumar P. (1978) Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the "cheese effect." Psychopharmacology 57, 33-38.
9. Fairbrother I. S., Arbuthnott G. W., Kelly J. S., and Butcher S. P. (1990) In vivo mechanisms underlying dopamine release from rat nigrostriatal terminals: studies using potassium and tyramine. J. Neurochem. 54, 1844-1851.
10. Fang J. and Yu P. H. (1994) Effect of l-deprenyl, its structural analogues and some monoamine oxidase inhibitors on dopamine uptake. Neuropharmacology 33, 763-768.
11. Finberg J. P. M., Wang J., Goldstein D. S., Kopin I. J., and Bankiewicz K. S. (1995) Influence of selective inhibition of monoamine oxidase A or B on striatal metabolism of L-DOPA in hemiparkinsonian rats. J. Neurochem. 65, 1213-1220.
12. Glover V. and Sandler M. (1986) Clinical chemistry of monoamine oxidase. Cell Biochem. Funct. 4, 89-97.
13. Green A. R., Mitchell B. D., Tordoff A. F. C., and Youdim M. B. H. (1977) Evidence for dopamine deamination by both type A and B monoamine oxidase in the rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine. Br. J. Pharmacol. 60, 343-349.
14. 3H]-catecholamines by homogenates of rat corpus striatum and cerebral cortex: effects of amphetamine analogues. Neuropharmacology 12, 669-679.
15. Heinonen E. H., Anttila M. I., and Lammintausta R. A. S. (1992) Pharmacokinetic and clinical pharmacology of selegiline, in Inhibitors of Monoamine Oxidase B (Szelenyi I., ed), pp. 201-213. Birkhauser Verlag Ag, Basel.
16. Houslay M. D., Tipton K. F., and Youdim M. B. H. (1976) Multiple forms of monoamine oxidase: fact and artifact. Life Sci. 19, 467-478.
17. Ishibashi K., Matsumoto T., Hirano M., Hirano H., Nakamura K., Nakahara T., and Uchimura H. (1986) β-Phenylethylamine (PEA) induced behavioral sensitization and changes in monoamine metabolism in discrete rat brain regions. Neurochem. Res. 11, 1799-1800.
18. Johnston J. P. (1968) Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem. Pharmacol. 17, 1285-1297.
19. Karoum F., Chuang L. W., Eisler T., Calne B. D., Liebowitz M. R., Quitkin F. M., Klein D. F., and Wyatt R. J. (1982) Metabolism of (-)deprenyl to amphetamine and methamphetamine may be responsible for deprenyl's therapeutic benefit: a biochemical assessment. Neurology 32, 503-509.
20. Kato T., Dong B., Ishii K., and Kinemuchi H. (1986) Brain dialysis: in vivo metabolism of dopamine and serotonin by monoamine oxidase A but not B in the striatum of unrestrained rats. J. Neurochem. 46, 1277-1282.
21. Knoll J. (1978) The possible mechanisms of action of (-)deprenyl in Parkinson's disease. J. Neural Transm. 43, 177-198.
22. Knoll J. (1983) Deprenyl (selegiline): the history of its development and pharmacological action. Acta Neurol. Scand. 95, 57-80.
23. Knoll J. (1985) The pharmacology of (-)-deprenyl. J. Neural Transm. Suppl. 22, 75-89.
24. Knoll J. (1987) R-(-)-Deprenyl (selegiline, Movergan R) facilitates the activity of the nigrostriatal dopaminergic neuron. J. Neural Transm. Suppl. 25, 45-66.
25. Knoll J. (1992) (-)Deprenyl medication: a strategy to modulate the age-related decline of the striatal dopaminergic system. J. Am. Geriatr. Soc. 40, 839-847.
26. Kuroki T., Tsutsumi T., Hirano M., Matsumoto T., Tatebayashi K., Nishiyama K., Uchimura H., Shiraishi A., Nakahara T., and Nakamura K. (1990) Behavioral sensitization to beta-phenylethylamine (PEA) : enduring modifications of specific dopaminergic neuron system in the rat. Psychopharmacology 102, 5-10.
27. Lauber J. and Waldmeier P. C. (1984) Determination of 2-phenylethylamine in rat brain after MAO inhibitors, and in human CSF and urine by capillary GC and chemical ionization MS. J. Neural Transm. 60, 247-264.
28. Levitt P., Pintar J. E., and Breakefield X. O. (1982) Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons. Proc. Natl. Acad. Sci. USA 79, 6385-6389.
29. Liccione J. and Azzaro A. J. (1988) Different roles for type A and type B monoamine oxidase in regulating synaptic dopamine at D-1 and D-2 receptors associated with adenosine-3′-5′-cyclic monophosphate (cyclic-AMP) formation. Naunyn Schmiedebergs Arch. Pharmacol. 337, 151-158.
30. Meeker J. E. and Reynolds P. C. (1990) Postmortem tissue methamphetamine concentrations following selegiline administration. J. Anal. Toxicol. 14, 330-331.
31. Nielsen J. A., Chapin D. S., and Moore K. E. (1983) Differential effects of d-amphetamine, β-phenylethylamine, cocaine and methylphenidate on the rate of dopamine synthesis in terminals of nigrostriatal and mesolimbic neurons and on the efflux of dopamine metabolites into cerebroventricular perfusates of rat. Life Sci. 33, 1899-1907.
32. O'Carrol A. M., Fowler C. J., Phillips J. P., Tobbia I., and Tipton K. F. (1983) The deamination of dopamine by human brain monoamine oxidase. Specificity for the two enzyme forms in seven brain regions. Naunyn Schmiedebergs Arch. Pharmacol. 332, 198-202.
33. Oguchi K. (1985) The effects of chronic and selective monoamine oxidase-A and -B inhibition on regional catecholamine levels in the rat brain. Biogenic Amines 3, 1-8.
34. Okuda C., Segal D. S., and Kuczenski R. (1992) Deprenyl alters behavior and caudate dopamine through amphetamine like action. Pharmacol. Biochem. Behav. 43, 1075-1080.
35. Oreland L. (1991) Monoamine oxidase, dopamine and Parkinson's disease. Acta Neural. Scand Suppl. 136, 60-65.
36. Oreland L., Fowler C. J., Carlsson A., and Magnusson T. (1980) Monoamine oxidase-A-and-B activity in the rat brain after hemitransection. Life Sci. 26, 139-146.
37. Otsaka S. and Kobayashi Y. (1964) A radioisotopic assay for monoamine oxidase determinations in human plasma. Biochem. Pharmacol. 13, 995-1006.
38. Paterson I. A., Juorio A. V., and Boulton A. A. (1990) 2-Phenylethylamine: a modulator of catecholamine transmission in the mammalian central nervous system? J. Neurochem. 55, 1827-1837.
39. Paterson I. A., Juorio A. V., Berry M. D., and Zhu M. Y. (1991) Inhibition of monoamine oxidase-B by (-)-deprenyl potentiates neuronal responses to dopamine agonists but does not inhibit dopamine catabolism in the rat striatum. J. Pharmacol. Exp. Ther. 258, 1019-1024.
40. Paxinos G. and Watson C. (1982) The Rat Brain in Stereotaxic Coordinates. Academic Press, Sydney.
41. Philips S. R. and Robson A. M. (1983a) Amphetamine-stimulated release of endogenous dopamine from the rat caudate nucleus in vivo. Neurochem. Res. 8, 731-741.
42. Philips S. R. and Robson A. M. (1983b) In vivo release of endogenous dopamine from rat caudate nucleus by phenylethylamine. Neuropharmacology 22, 1297-1301.
43. Reynolds G. P., Elsworth J. D., Blau K., Sandler M., Lees A. J., and Stern G. M. (1978) Deprenyl is metabolized to methamphetamine and amphetamine in man. Br. J. Clin. Pharmacol. 6, 542-544.
44. Riederer P., Conradi C., Schay V., Kienzl E., Birkmayer G., Danielczyk W., Sofic C, and Youdim M. B. H. (1986) Localization of MAO-A and MAO-B in human brain: a step in understanding the therapeutic action of L-deprenyl, in Advances in Neurology, Vol. 45 (Yahr M. D. and Bergman K. J., eds), pp. 111-118. Raven Press. New York.
45. Schachter M., Marsden C. D., Parker J. D., Jenner P., and Testa B. (1980) Deprenyl in the management of response fluctuations in patients with Parkinson's disease on levodopa. J. Neurol. Neurosurg. Psychiatry 43, 1016-1021.
46. Tipton K. F. and Mantle T. J. (1981) The inhibition of rat liver monoamine oxidase by clorgyline and deprenyl, in Monoamine Oxidase Inhibitors. The State of Art (Youdim M. B. H. and Paykel E. S., eds), pp. 3-15. Wiley, New York.
47. Turkish S., Yu P. H., and Greenshaw A. J. (1988) Monoamine oxidase-B inhibition: a comparison of in vivo and ex vivo measures of reversible effects. J. Neural Transm. 74, 141-148.
48. Wachtel S. R. and Abercrombie E. D. (1994) L-3,4,-Dihydroxyphenylalanine-induced dopamine release in the striatum of intact and 6-hydroxydopamine-treated rats: differential effects of monoamine oxidase A and B inhibitors. J. Neurochem. 63, 108-117.
49. Waldmeier P. C. and Feiner A. E. (1978) Deprenyl: loss of selectivity for inhibition of B-type MAO after repeated treatment. Biochem. Pharmacol. 27, 801-802.
50. Waldmeier P. C., Feiner A. E., and Maitre L. (1981) Long term effects of selective MAO inhibitors on MAO activity and amine metabolism, in Monoamine Oxidase Inhibitors. The State of Art (Youdim M. B. H. and Paykel E. S., eds), pp. 87-102. Wiley, New York.
51. Westlund K. N., Krakower T. J., Kwan S. W., and Abell C. W. (1993) Intracellular distribution of monoamine oxidase A in selected regions of rat and monkey brain and spinal cord. Brain Res. 612, 221-230.
52. Wiener H. L., Hashima A., Lajtha A., and Sershen H. (1989) Chronic L-deprenyl induced up regulation of the dopamine uptake carrier. Eur. J. Pharmacol. 163, 191-194.
53. Yang H. Y. T. and Neff N. H. (1974) The monoamine oxidase of brain: selective inhibition with drugs and the consequence for the metabolism of biogenic amines. J. Pharmacol. Exp. Ther. 189, 733-740.
54. Zetterström T., Sharp T., Collin A. K., and Ungerstedt U. (1988) In vivo measurement of extracellular dopamine and DOPAC in rat striatum after various dopamine-releasing drugs; implications for the origin of extracellular DOPAC. Eur. J. Pharmacol. 148, 327-334.
55. 3H] imipramine binding and decreases β-adrenergic receptor function. Eur. J. Pharmacol. 89, 111-117.
56. Zsilla G., Foldi P., Held G., Szekely A. M., and Knoll J. (1986) The effect of repeated doses of (-)deprenyl on the dynamics of monoaminergic transmission. Comparison with clorgyline. Pol. J. Pharmacol. Pharm. 38, 57-67.